🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy

Recruitingn/aAges 65 Years - anyAllUniversity Hospital Freiburg
NCT05337631 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing; however, the evidence regarding the ideal treatment for this often vulnerable and frail patient cohort is limited. Although the benefit of concomitant chemotherapy has been reported to decrease in elderly HNSCC patients based on the MACH-NC meta-analysis, it remains unknown whether state-of-the art radiotherapy techniques such as intensity-modulated radiotherapy (IMRT), modern supportive treatments and alternative chemotherapy fractionation (e.g., cisplatin weekly) may have altered this observation. The objective of this retrospective multinational multicenter study is to determine the oncological outcomes of elderly patients (≥65 years) with locally advanced HNSCCs undergoing definitive (chemo-)radiation and to investigate the influence of concomitant chemotherapy on overall survival and progress

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * definitive (chemo-)radiotherapy of locoregionally advanced (cT3-4 and/or cN+) head-and-neck squamous cell carcinomas (HNSCC) of the oral cavity, oropharynx, hypopharynx or larynx * primary treatment since 2005 * age ≥65 years at the time of (chemo-)radiotherapy Exclusion Criteria: * adjuvant (chemo-)radiotherapy * history of previous head-and-neck cancers or radiotherapy in the head-and-neck region * distant metastases at (chemo-)radiotherapy initiation (cM1) * HNSCCs of the nasopharynx, salivary glands, skin or with unknown primary
💊

What it tests

  • Not listed
📍

Where

18 sites
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine
Baltimore, United States
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai
New York, United States
Department of Radiation Oncology, Case Western Reserve University
Cleveland, United States
Division of Radiation Oncology, The Ohio State University Wexner
Columbus, United States
Radiation Oncology Department, German Oncology Center
Limassol, Cyprus
Brno University Hospital
Brno, Czechia
Department of Radiooncology and Radiotherapy, Charité-Universitätsmedizin Berlin
Berlin, Germany
Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg
Erlangen, Germany

…and 10 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy